Company intelligence / Profile preview

ImmuNovX Biotech

Conshohocken, Pennsylvania, United Statesimmunovx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

ImmuNovX is developing a platform technology called LR3N-CS that chemically binds the DNA of treated pathogens via a cell-free manufacturing process, resulting in live-attenuated, replication-defective DNA pathogens. The company is in early stages with no clinical results reported yet.

Therapeutic areas: Infectious Diseases
Modalities: DNA vaccines
Industry: Biotech

Partnerships

Actively seeking partners

Beyond the preview

Go deeper on ImmuNovX Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmuNovX Biotech.

Explore the full profile